Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic Review

Table 1

Groups of treatment regimens (grouping of similar arms) and pure groups.

Number	Regimen	Studies (references)	Number of arms	N	Number of “pure” arms	N in “pure” arms
1	ASA + PA + TP + UFH + GPI	[12–19]	13	9,369	10	4,997
2	ASA + PA + TP + DTI	[20]	1	1,800	1	1,800
3	ASA + PA + TP + UFH + GPI + FS	[21]	1	298	1	298
4	ASA + TP + UFH + GPI + FS	[21]	1	300	1	300
5	ASA + UFH + FS	[22–43]	38	104,754	33	82,283
6	ASA + UFH + GPI + FS	[22]	1	8,328	1	8,328
7	ASA + PA + GPI	[44]	1	2,885	—	—
8	ASA + PA + TP + GPI	[44]	1	2,860	—	—
9	ASA + LMWH + FS	[23, 45]	2	12,296	1	2,040
10	ASA + PA + TP + UFH	[12, 14, 15, 46, 47]	5	2,647	3	1,922
11	ASA + TP + LMWH + FS	[45]	1	818	—	—
12	ASA + TP + UFH + FS	[39, 45, 46]	3	2,992	—	—
13	ASA + LMWH + KS	[48]	1	253	1	253
14	ASA + KS	[30, 48–53]	7	29,824	4	3,428
15	ASA + DTI + KS	[54, 55]	2	9,119	2	9,119
16	ASA + UFH + KS	[30, 32, 36, 37, 40, 55–60]	15	75,382	13	46,292
17	ASA + PA + UFH	[27, 61]	3	826	2	584
18	ASA + FS	[30, 41, 52, 53, 62]	7	38,298	2	1,471
19	ASA + UFH + FS + KS	[40, 60]	2	10,471	2	10,471
20	ASA + PA + UFH + GPI	[61]	1	241	1	241
21	ASA + DTI + FS	[34]	1	1,511	—	—
22	TP + KS	[51]	1	450	1	450
23	UFH + FS	[63, 64]	2	3,136	2	3,136
24	UFH	[63–65]	3	4,200	3	4,200
25	ASA + UFH	[38, 42, 58, 59]	4	4,387	3	1,512
26	ASA	[49, 50]	2	10,854	1	2,259
27	ASA + PA + UFH + FS	[66]	1	195	—	—
28	ASA + TP + LMWH + GPI + FS	[67]	1	522	—	—
29	ASA + PA + TP + LMWH + GPI + FS	[67]	1	537	—	—
30	ASA + TP + UFH + KS	[56]	1	22,961	—	—
31	ASA + TP + KS	[68, 69]	2	13,846	—	—
32	ASA + TP + LMWH + KS	[68, 69]	2	13,816	—	—
33	ASA + PA + TP + UFH + FS	[17]	1	829	—	—
34	KS	[70, 71]	2	6,211	—	—
35	UFH + KS	[65, 70]	2	1,488	—	—

ASA: acetylsalicyclic acid, PA: primary angioplasty, TP: thienopyridines, UFH: unfractionated heparin, LMWH: low molecular weight heparin, GPI: glycoprotein IIbIIIa inhibitors, DTI: direct thrombin inhibitors, FS: fibrin specific thrombolytics and KS: kinase type thrombolytics (streptokinase and urokinase).